摘要
新型冠状病毒肺炎(COVID-19)仍在世界范围内流行,系统性硬化症(SSc)患者因常继发间质性肺疾病且广泛使用激素及免疫抑制剂而在疫情期间应受到关注,其一旦感染则面临着疾病恶化甚至死亡的风险。因此世界硬皮病基金会(WSF)针对COVID-19大流行提出了SSc患者的管理建议,本文通过对该建议进行解读与评析,对目前SSc合并COVID-19治疗手段进行了总结与展望,为SSc患者在COVID-19大流行下的临床治疗提供参考。
Currently,COVID-19 continues to overwhelmingly hit almost all the countries of the world.It is noteworthy that patients with systemic sclerosis are considered to be a group at risk for disease deterioration and even death when they get infected COVID-19 due to the co-morbidity of interstitial lung disease and widespread use of glucocorticoids and immunosuppressive agents.In this case,the World Scleroderma Foundation put forward recommendations for the management of patients with SSc.We introduced and interpreted these recommendations,with a summary of present treatment strategies for SSc patients with COVID-19,aiming to provide more options for clinical management of these patients.
作者
崔洁涵
杨林
汪晓平
何晶晶
彭晓欣
冯星
马隽
刘爱京
CUI Jiehan;YANG Lin;WANG Xiaoping;HE Jingjing;PENG Xiaoxin;FENG Xing;MA Jun;LIU Aijing(Department of Rheumatology and Immunology,the Second Hospital of Hebei Medical University,Shijiazhuang 050000,China;Hebei Medical University,Shijiazhuang 050000,China;Hebei Research Center for Stem Cells Medical Translational Engineering,Shijiazhuang 050000,China;Department of Anatomy,Hebei Medical University,Shijiazhuang 050000,China)
出处
《中国全科医学》
CAS
北大核心
2021年第17期2218-2223,2229,共7页
Chinese General Practice
基金
河北省医学科学研究课题计划(20190552)。
